AURKA inhibition with shRNA also demonstrated to partially reverse fibroblast-mediated resistance to gefitinib in EGFR-mutated NSCLC cells co-cultured with stromal cells (59). This evidence concerns the gene EGFR and non-small cell lung carcinoma.